The presentations will be available in the Publications ... including Novartis' Zolgensma ® for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have ...
Del-zota produced statistically significant increases in exon skipping and dystrophin levels in EXPLORE44, a Phase 1/2 study in patients with DMD44 (oral presentation) Aravindhan Veerapandiyan ...
Muscular Dystrophy Association Clinical & Scientific Conference, convening in Dallas, Texas, from March 16-18, will feature ...
Oral Presentation: Title: First-in-human Phase 1 study of orally administered SAT-3247 in healthy volunteers and adult participants with Duchenne Muscular Dystrophy (DMD) Date: Wednesday ...
The oral presentations feature data from the ongoing CONNECT1-EDO51 clinical trial in Duchenne muscular dystrophy (DMD) and from the ongoing FREEDOM-DM1 clinical trial in myotonic dystrophy type 1 ...
will present topline del-zota data from Avidity's Phase 1/2 EXPLORE44 trial for people living with Duchenne Muscular Dystrophy amenable to exon 44 skipping (DMD44). March 16-18, 2025: 6:00 p.m ...
today announced an oral presentation at the upcoming 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference being held March 16-19 in Dallas. “The oral presentation at this ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback